CY1108572T1 - Φαρμακα για nοσους του αμφιβληστροειδους και του χορειοειδους χιτωνα που περιεχουν στερεοειδη ως δραστικο συστατικο - Google Patents

Φαρμακα για nοσους του αμφιβληστροειδους και του χορειοειδους χιτωνα που περιεχουν στερεοειδη ως δραστικο συστατικο

Info

Publication number
CY1108572T1
CY1108572T1 CY20081101320T CY081101320T CY1108572T1 CY 1108572 T1 CY1108572 T1 CY 1108572T1 CY 20081101320 T CY20081101320 T CY 20081101320T CY 081101320 T CY081101320 T CY 081101320T CY 1108572 T1 CY1108572 T1 CY 1108572T1
Authority
CY
Cyprus
Prior art keywords
active ingredient
steeroid
medicines
diseases
extracts containing
Prior art date
Application number
CY20081101320T
Other languages
English (en)
Inventor
Yasuo Tano
Tatsuji Kurose
Original Assignee
Santen Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd filed Critical Santen Pharmaceutical Co., Ltd
Publication of CY1108572T1 publication Critical patent/CY1108572T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Chemistry (AREA)
  • Steroid Compounds (AREA)

Abstract

Ένας στόχος της παρούσας εφεύρεσης είναι να παράσχει θεραπευτικούς παράγοντες για διαταραχές του αμφιβληστροειδούς και του χοριοειδούς που περιλαμβάνουν ένα στεροειδές ως ένα δραστικό συστατικό και που έχουν βελτιωμένες επιδράσεις και δοσολογικές μορφές για θεραπεία των διαταραχών του αμφιβληστροειδούς και του χοριοειδούς όπου το στεροειδές μπορεί να χορηγείται εύκολα. Η παρούσα εφεύρεση αφορά σε θεραπευτικούς παράγοντες για διαταραχές του αμφιβληστροειδούς και του χοριοειδούς που περιλαμβάνουν βηταμεθαζόνη ή υδροκορτιζόνη ως ένα δραστικό συστατικό και σε εγχύσεις κάτω από τον επιπεφυκότα που περιλαμβάνουν το στεροειδές ως ένα δραστικό συστατικό.
CY20081101320T 2001-03-28 2008-11-17 Φαρμακα για nοσους του αμφιβληστροειδους και του χορειοειδους χιτωνα που περιεχουν στερεοειδη ως δραστικο συστατικο CY1108572T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001092329 2001-03-28
EP02708676A EP1380302B1 (en) 2001-03-28 2002-03-27 Remedies for retina and choroid diseases containing steroids as the active ingredient

Publications (1)

Publication Number Publication Date
CY1108572T1 true CY1108572T1 (el) 2014-04-09

Family

ID=18946808

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101320T CY1108572T1 (el) 2001-03-28 2008-11-17 Φαρμακα για nοσους του αμφιβληστροειδους και του χορειοειδους χιτωνα που περιεχουν στερεοειδη ως δραστικο συστατικο

Country Status (12)

Country Link
US (1) US20040097478A1 (el)
EP (1) EP1380302B1 (el)
KR (1) KR100854058B1 (el)
CN (1) CN100353947C (el)
AT (1) ATE405274T1 (el)
CA (1) CA2442296C (el)
CY (1) CY1108572T1 (el)
DE (1) DE60228431D1 (el)
DK (1) DK1380302T3 (el)
ES (1) ES2311592T3 (el)
PT (1) PT1380302E (el)
WO (1) WO2002078713A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI347847B (en) * 2003-08-20 2011-09-01 Santen Pharmaceutical Co Ltd Drug delivery system for sub-tenon administration of fine particles
US7374219B2 (en) * 2004-09-22 2008-05-20 Zephyros, Inc. Structural reinforcement member and method of use therefor
RU2696045C1 (ru) * 2018-10-15 2019-07-30 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения болезни Илза
IT201900014052A1 (it) * 2019-08-05 2021-02-05 Lucia Scorolli Preparazione para-bulbare con effetto citotrofico-retinico

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
JPS61106521A (ja) * 1984-10-31 1986-05-24 Kureha Chem Ind Co Ltd 血管増殖抑制剤
DE69032012T2 (de) * 1989-08-28 1998-05-14 Alcon Lab Inc Ophthalmische zubereitung
US5104787A (en) * 1990-03-05 1992-04-14 Lindstrom Richard L Method for apparatus for a defined serumfree medical solution useful for corneal preservation
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
WO1993010141A2 (en) * 1991-11-22 1993-05-27 Alcon Laboratories, Inc. Angiostatic steroids
JPH08503921A (ja) * 1991-12-20 1996-04-30 アメリカ合衆国 カポジ肉腫を処置、及び脈管浸透を阻止又は阻害するための方法
WO1995003807A1 (en) * 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
AU6763496A (en) * 1995-08-07 1997-03-05 Schering Corporation Treatment of ocular inflammatory conditions with interleukin-10
ATE493983T1 (de) * 1996-11-05 2011-01-15 Childrens Medical Center Thalidomide und dexamethason für die behandlung von tumors
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6395294B1 (en) * 2000-01-13 2002-05-28 Gholam A. Peyman Method of visualization of the vitreous during vitrectomy
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye

Also Published As

Publication number Publication date
US20040097478A1 (en) 2004-05-20
EP1380302A4 (en) 2006-04-12
KR20030087029A (ko) 2003-11-12
CN1551775A (zh) 2004-12-01
DK1380302T3 (da) 2008-12-08
CN100353947C (zh) 2007-12-12
PT1380302E (pt) 2008-11-25
ES2311592T3 (es) 2009-02-16
EP1380302A1 (en) 2004-01-14
CA2442296C (en) 2010-06-22
KR100854058B1 (ko) 2008-08-26
WO2002078713A1 (fr) 2002-10-10
ATE405274T1 (de) 2008-09-15
CA2442296A1 (en) 2002-10-10
DE60228431D1 (de) 2008-10-02
EP1380302B1 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
ATE246919T1 (de) Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson
TW200505402A (en) Ophthalmic drug delivery device
ATE251901T1 (de) Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson
DE60322436D1 (de) Verabreichung von capsaicinoiden
PT1165085E (pt) Derivados de ftalazina para tratar doencas inflamatorias
PA8635901A1 (es) Nucleosidos de 3-beta-d-ribofuranosiltiazolo [4,5-d] pirimidina y usos de los mismos
ATE365550T1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
SE9704644D0 (sv) New use
CY1108572T1 (el) Φαρμακα για nοσους του αμφιβληστροειδους και του χορειοειδους χιτωνα που περιεχουν στερεοειδη ως δραστικο συστατικο
DK1343472T3 (da) Thixotropisk næsespray
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
ATE251905T1 (de) Verwendung von ubiquinon q 10 zur vorbeugung und behandlung von postoperativen okularen pathologien
KR102199560B1 (ko) 니코틴성 아세틸콜린 수용체 작용제로 부비점막 질환을 치료하기 위한 조성물 및 방법
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
MXPA01011344A (es) El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.
Razmi T et al. Recent advances in pathogenesis and medical management of vitiligo
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
Priyadarshini et al. Traversing the “Wickham striae” from pathogenesis, diagnosis to the therapeutic management: a comprehensive review
BR112018067718B1 (pt) Composições para tratamento de doenças da mucosa nasal e paranasal com agonistas do receptor de acetilcolina nicotínica
UA30143A (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
UA2699U (uk) Спосіб лікування автоімунного тиреоїдиту
UA91697C2 (en) 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF